Co-Authors
This is a "connection" page, showing publications co-authored by Michael Liptay and Gary Chmielewski.
Connection Strength
0.289
-
Improved False-Positive Rates and the Overestimation of Unintended Harm from Lung Cancer Screening. Lung. 2019 06; 197(3):327-332.
Score: 0.148
-
Understanding barriers to lung cancer screening in primary care. J Thorac Dis. 2020 May; 12(5):2536-2544.
Score: 0.040
-
Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
Score: 0.027
-
Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):727-34.e1-3; discussion 734.
Score: 0.027
-
Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol. 2013 Jan; 8(1):31-6.
Score: 0.024
-
Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
Score: 0.023